Hikma Pharmaceuticals (LON:HIK) Stock Price Crosses Above 200 Day Moving Average – Here’s What Happened

Hikma Pharmaceuticals PLC (LON:HIK) shares crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 2,016.45 ($26.11) and traded as high as GBX 2,034 ($26.33). Hikma Pharmaceuticals shares last traded at GBX 2,010 ($26.02), with a volume of 35,338,895 shares traded.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on HIK shares. JPMorgan Chase & Co. reissued an “overweight” rating on shares of Hikma Pharmaceuticals in a research note on Friday, March 7th. Berenberg Bank reiterated a “buy” rating and set a GBX 2,560 ($33.14) price objective on shares of Hikma Pharmaceuticals in a report on Monday, March 10th.

Hikma Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 55.82, a current ratio of 1.66 and a quick ratio of 1.27. The company’s fifty day moving average price is GBX 2,178.08 and its 200 day moving average price is GBX 2,016.64. The company has a market cap of £5.54 billion, a PE ratio of 19.60, a P/E/G ratio of 2.38 and a beta of 0.41.

Hikma Pharmaceuticals Increases Dividend

The company also recently disclosed a dividend, which will be paid on Thursday, May 1st. Shareholders of record on Thursday, March 20th will be given a $0.48 dividend. This represents a yield of 1.8%. This is an increase from Hikma Pharmaceuticals’s previous dividend of $0.32. The ex-dividend date of this dividend is Thursday, March 20th. Hikma Pharmaceuticals’s dividend payout ratio is presently 60.84%.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.